EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial

医学 放射治疗 外束辐射 食管癌 紫杉醇 随机对照试验 化疗 外科 内科学 癌症
作者
John M. DeWitt,S. Krishna Murthy,Ramesh Ardhanari,G. Aaron DuVall,Grzegorz T. Wallner,Paul Litka,Claire Daugherty,Kirk D. Fowers
出处
期刊:Gastrointestinal Endoscopy [Elsevier BV]
卷期号:86 (1): 140-149 被引量:30
标识
DOI:10.1016/j.gie.2016.11.017
摘要

OncoGel (Protherics Salt Lake City, Inc, Salt Lake City, UT) is paclitaxel (PTX) formulated in a thermosensitive, biodegradable copolymer for focused cytotoxicity and radiosensitization. A phase 2a study suggested that EUS-guided PTX injection into esophageal tumors subsequently receiving radiotherapy was safe.In an international multicenter, prospective, randomized phase 2b study, patients with local or locoregional adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus/gastroesophageal junction and eligible for neoadjuvant chemoradiotherapy (CRT) before surgery were randomized to standard of care (SOC) plus EUS-guided PTX injection or SOC alone. PTX was injected in 0.5 to 1.0 mL aliquots throughout the tumor. Planned CRT as SOC was intravenous 5-fluorouracil for the first 4 days (weeks 1 and 5), intravenous cisplatin on the first day of each 5-fluorouracil course, and radiotherapy over 5.5 weeks. Patients were evaluated weekly during CRT and re-evaluated at 12 weeks for surgical eligibility and CT for change in overall tumor volume.The analysis included 137 patients (97 males; mean age, 58 ± 9.1 years) randomized to PTX + SOC (n = 72) and SOC (n = 65) by using a modified intention-to-treat approach. Overall response by tumor volume between the PTX (12.5%) and the SOC group (20.0%; P = .24; odds ratio, 0.57; 95% confidence interval, 0.23-1.44) was similar. Pathologic complete response was higher in the SOC group (26.2% vs 12.5%; P = .046); however, 12-month survival (P = .412) and the overall frequency of 1 or more adverse events (P = .17) were similar between the 2 groups.SOC + PTX is safe but does not improve overall survival or overall tumor response at the primary tumor site for patients with local or locoregional cancer of the esophagus/gastroesophageal junction. (Clinical trial registration number: NCT00573131.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
烟花的应助被明亮采纳,获得10
刚刚
1秒前
沐沐完成签到,获得积分10
1秒前
鲤鱼鑫磊发布了新的文献求助10
2秒前
2秒前
好眠哈密瓜完成签到 ,获得积分10
2秒前
2秒前
胡子木完成签到 ,获得积分10
2秒前
超自然完成签到,获得积分10
4秒前
小丸子发布了新的文献求助10
4秒前
zyy发布了新的文献求助10
5秒前
5秒前
univ完成签到,获得积分10
5秒前
5秒前
忧伤的坤完成签到 ,获得积分10
6秒前
bengbeng完成签到,获得积分10
6秒前
王誉霖完成签到,获得积分10
7秒前
7秒前
林见鹿完成签到,获得积分10
7秒前
7秒前
田様的应助被mm采纳,获得10
8秒前
赘婿的应助被心心采纳,获得10
8秒前
8秒前
会笑的猪猪猫完成签到,获得积分10
9秒前
比格大王完成签到,获得积分10
9秒前
嘟嘟发布了新的文献求助10
10秒前
daomaihu发布了新的文献求助100
10秒前
ygchyh发布了新的文献求助10
10秒前
10秒前
Popeye完成签到,获得积分10
11秒前
廾匸关注了科研通微信公众号
11秒前
11秒前
11秒前
丑鸭子完成签到,获得积分10
13秒前
13秒前
13秒前
dd完成签到,获得积分10
13秒前
墨落成白完成签到,获得积分10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820